Victory Capital Management Inc. Grows Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Victory Capital Management Inc. grew its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 88.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,640 shares of the company's stock after acquiring an additional 26,560 shares during the quarter. Victory Capital Management Inc. owned about 0.11% of Tyra Biosciences worth $787,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. US Bancorp DE acquired a new stake in Tyra Biosciences during the fourth quarter worth about $50,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Tyra Biosciences during the 4th quarter worth approximately $149,000. Franklin Resources Inc. purchased a new stake in shares of Tyra Biosciences during the 3rd quarter valued at approximately $278,000. Valence8 US LP acquired a new position in Tyra Biosciences in the third quarter valued at approximately $310,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Tyra Biosciences in the third quarter valued at approximately $333,000. Hedge funds and other institutional investors own 84.14% of the company's stock.

Insider Transactions at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 3,993 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the sale, the director now owns 3,707,420 shares of the company's stock, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is currently owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. UBS Group initiated coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences has an average rating of "Buy" and a consensus target price of $30.50.

Tyra Biosciences Trading Down 0.4 %

TYRA traded down $0.04 during mid-day trading on Monday, hitting $10.65. 116,730 shares of the stock were exchanged, compared to its average volume of 230,029. The firm's fifty day moving average is $13.05 and its two-hundred day moving average is $16.68. Tyra Biosciences, Inc. has a 1-year low of $9.93 and a 1-year high of $29.60. The company has a market cap of $538.92 million, a PE ratio of -6.61 and a beta of 1.09.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.